Review ArticlesStrategies to Overcome High-Risk Multiple MyelomaSanchez, Larysa MD Author Information From the Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. The author has disclosed that she has no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Larysa Sanchez, MD, Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, The Mount Sinai Hospital, One Gustave L. Levy Place, Box 1185, New York, NY 10029-6574. E-mail: [email protected]. The Cancer Journal: 5/6 2021 - Volume 27 - Issue 3 - p 201-204 doi: 10.1097/PPO.0000000000000529 Buy Metrics Abstract Multiple myeloma (MM) patients with high-risk cytogenetics continue to have inferior outcomes despite recent advances in the treatment of MM. As defined by the International Myeloma Working Group, the presence of t(4;14), t(14;16), del(17p), t(14;20) and amplification of 1q are considered to be high-risk chromosomal abnormalities associated with poor survival. Despite the use of immunomodulatory agents, proteasome inhibitors, autologous stem cell transplantation, and anti-CD38 monoclonal antibodies, clinical trials of current therapies have not shown strong statistical evidence of being able to overcome the poor prognosis of high-risk disease. Novel treatment approaches are urgently needed to improve survival in this subset of MM patients. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.